ArticleFrontiers in oncology2026
Self-learning GAN based synthetic CT generation: unlocking CBCT-based adaptive radiotherapy.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Implementation of an AI-Driven Workflow for Daily Dose Reconstruction in Prostate Cancer Radiotherapy.Cancers · 2026Article
- A clinical evaluation of HyperSight CBCT enhanced offline adaptive breast radiotherapy.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose/objectives: This study proposes and clinically evaluates synthetic CT (sCT) images generated from multi-center CBCT scans using artificial intelligence, with the aim of fully leveraging CBCT for adaptive radiotherapy in patients with pelvic, head-and-neck, lung, and breast cancer. Materials and methods: In collaboration with TheraPanacea (Paris, France), AI-based sCT models were developed for multiple anatomical sites using a cycleGAN architecture. The study included 51 patients from two European institutions diagnosed with head-and-neck, lung, pelvic or breast cancer and treated with CBCT-based position verification. CBCT scans were acquired using two linear accelerator systems (Varian and Elekta). Image accuracy was assessed using MAE, SSIM, and PSNR. For dosimetric evaluation, planning CTs (pCTs) were non-rigidly registered to CBCTs. Treatment plans were created on the pCT using a clinical TPS to meet standard clinical criteria, then recalculated on both the warped CT (wCT) and sCT. Dose distributions were compared using global gamma passing rates and dose-volume metrics. Results: The proposed model substantially improved image quality compared with CBCT. MAE decreased from 122.95 ± 50.07 to 23.65 ± 10.09, while SSIM increased from 0.78 ± 0.12 to 0.97 ± 0.03 and PSNR from 35.01 ± 7.24 to 44.35 ± 7.07. Dose-metric comparisons showed strong agreement between the pCT and wCT, with median relative differences within 0.5% for both targets and organs at risk. Median gamma passing rates for 2%/2 mm and 3%/3 mm criteria (10% threshold) reached 100% across all anatomical sites. No performance differences were observed between Elekta- and Varian-sCTs. Conclusion: This multi-center study demonstrates the feasibility of generating clinically acceptable AI-based sCTs from CBCT for multiple anatomical sites, yielding consistent image quality improvements and reliable dosimetric accuracy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.